Document Detail

Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial.
MedLine Citation:
PMID:  8759069     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: RheothRx (poloxamer 188) is a surfactant with hemorheological and antithrombotic properties that reduces myocardial reperfusion injury in animal models of myocardial infarction. The purpose of the present study was to evaluate the safety and efficacy of adjunctive therapy with poloxamer 188 in patients receiving thrombolytic therapy for acute myocardial infarction. METHODS AND RESULTS: In this multicenter trial, we randomized 114 patients to a 48-hour infusion of poloxamer 188 or vehicle placebo beginning immediately after the initiation of thrombolytic therapy. Tomographic imaging with 99mTc sestamibi before reperfusion and again 5 to 7 days after the infarction was used to determine myocardium at risk for infarction, infarct size, and myocardial salvage. Radionuclide angiography at 5 to 7 days after infarction was used to measure left ventricular ejection fraction. The treated and control groups had comparable baseline characteristics, time to thrombolytic administration, and time to treatment with poloxamer 188 or placebo. Poloxamer 188-treated patients demonstrated a 38% reduction in median myocardial infarct size (25th and 75th percentile) compared with placebo (16% [7, 30] versus 26% [9, 43]; P = .031), greater median myocardial salvage (13% [7, 20] versus 4% [1, 15]; P = .033), and a 13% relative improvement in median ejection fraction (52% [43, 60] versus 46% [35, 60]; P = .020). Poloxamer 188 treatment also resulted in a reduced incidence of reinfarction (1% versus 13%; P = .016). Poloxamer 188 was well tolerated without adverse hemodynamic effects or significant organ toxicity. CONCLUSIONS: Adjunctive therapy with poloxamer 188 resulted in substantial benefit in this randomized trial, including significantly smaller infarcts, greater myocardial salvage, better left ventricular function, and a lower incidence of in-hospital reinfarction. Although the mechanisms are unproven, poloxamer 188 treatment may accelerate thrombolysis, reduce reocclusion, and ameliorate reperfusion injury.
G L Schaer; L J Spaccavento; K F Browne; K A Krueger; D Krichbaum; J M Phelan; W O Fletcher; C L Grines; S Edwards; M K Jolly; R J Gibbons
Related Documents :
2061979 - Selection bias in the use of thrombolytic therapy in acute myocardial infarction. the s...
7935639 - Knowledge and practices of generalist and specialist physicians regarding drug therapy ...
7480969 - Treatment of myocardial infarction: hypotensive effect of different thrombolytic agents.
3097099 - Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate ...
2660919 - Thrombolytic therapy and acute myocardial infarction.
3527809 - Significance of infarct site and methylprednisolone on survival following acute myocard...
3628329 - Circadian rhythm of ventricular tachycardia.
16206909 - High resolution optical imaging of infarction in intact organs.
16092589 - Atypical presentation of eosinophilic endomyocardial disease.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  94     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1996 Aug 
Date Detail:
Created Date:  1996-12-11     Completed Date:  1996-12-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  298-307     Citation Subset:  AIM; IM    
Section of Cardiology, Rush Medical College, Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Coronary Angiography
Double-Blind Method
Fibrinolytic Agents / therapeutic use
Middle Aged
Myocardial Infarction / radiography,  therapy*
Poloxalene / adverse effects,  therapeutic use*
Salvage Therapy
Technetium Tc 99m Sestamibi / diagnostic use
Thrombolytic Therapy*
Treatment Outcome
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Placebos; 109581-73-9/Technetium Tc 99m Sestamibi; 9003-11-6/Poloxalene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of myocardial perfusion reserve before and after coronary balloon predilatation and after...
Next Document:  Only hibernating myocardium invariably shows early recovery after coronary revascularization.